HUP9902769A3 - Eprosartan dihydrate and a process for its production and formulation - Google Patents

Eprosartan dihydrate and a process for its production and formulation

Info

Publication number
HUP9902769A3
HUP9902769A3 HU9902769A HUP9902769A HUP9902769A3 HU P9902769 A3 HUP9902769 A3 HU P9902769A3 HU 9902769 A HU9902769 A HU 9902769A HU P9902769 A HUP9902769 A HU P9902769A HU P9902769 A3 HUP9902769 A3 HU P9902769A3
Authority
HU
Hungary
Prior art keywords
formulation
production
eprosartan
dihydrate
eprosartan dihydrate
Prior art date
Application number
HU9902769A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21765344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9902769(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of HUP9902769A2 publication Critical patent/HUP9902769A2/hu
Publication of HUP9902769A3 publication Critical patent/HUP9902769A3/hu
Publication of HU228263B1 publication Critical patent/HU228263B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU9902769A 1996-03-29 1997-03-26 Eprosartan dihydrate and a process for its production and formulation HU228263B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1441496P 1996-03-29 1996-03-29
PCT/US1997/004877 WO1997036874A1 (en) 1996-03-29 1997-03-26 Eprosartan dihydrate and a process for its production and formulation

Publications (3)

Publication Number Publication Date
HUP9902769A2 HUP9902769A2 (hu) 2000-03-28
HUP9902769A3 true HUP9902769A3 (en) 2000-04-28
HU228263B1 HU228263B1 (en) 2013-02-28

Family

ID=21765344

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902769A HU228263B1 (en) 1996-03-29 1997-03-26 Eprosartan dihydrate and a process for its production and formulation

Country Status (36)

Country Link
EP (1) EP0889880B1 (hu)
JP (1) JP4316013B2 (hu)
CN (2) CN1214682A (hu)
AP (1) AP901A (hu)
AR (1) AR006439A1 (hu)
AT (1) ATE239723T1 (hu)
AU (1) AU726694B2 (hu)
BG (1) BG64095B1 (hu)
BR (1) BR9708336A (hu)
CA (1) CA2250395C (hu)
CZ (1) CZ293345B6 (hu)
DE (1) DE69721749T2 (hu)
DK (1) DK0889880T3 (hu)
DZ (1) DZ2199A1 (hu)
EA (1) EA001958B1 (hu)
EG (1) EG23889A (hu)
ES (1) ES2198564T3 (hu)
HK (1) HK1016594A1 (hu)
HU (1) HU228263B1 (hu)
ID (1) ID16507A (hu)
IL (1) IL126319A0 (hu)
MA (1) MA24437A1 (hu)
MY (1) MY117682A (hu)
NO (2) NO311760B1 (hu)
NZ (1) NZ332008A (hu)
OA (1) OA11176A (hu)
PL (1) PL188816B1 (hu)
PT (1) PT889880E (hu)
RO (1) RO118870B1 (hu)
SK (1) SK282346B6 (hu)
TR (1) TR199801954T2 (hu)
TW (1) TW434239B (hu)
UA (1) UA49880C2 (hu)
UY (1) UY24504A1 (hu)
WO (1) WO1997036874A1 (hu)
ZA (1) ZA972686B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0991647B1 (en) * 1997-06-27 2002-09-04 Smithkline Beecham Corporation Eprosartan monohydrate
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
KR100597922B1 (ko) * 1997-11-17 2006-07-10 스미스클라인 비참 코포레이션 고용량 약물 로딩 속효성 및 변형 방출형 경구 투여용제형 및 그의 제조 방법
ZA991706B (en) 1998-03-04 2000-10-03 Takeda Chemical Industries Ltd Sustained-release preparation for Aii Antagonist, production and use thereof.
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
PL193673B1 (pl) * 1998-07-20 2007-03-30 Smithkline Beecham Corp Bezpostaciowa sól amonowa eprosartanu,jej granulat i biologicznie ulepszony preparat oraz sposoby ich wytwarzania i zastosowanie
GB9820405D0 (en) 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU1157500A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
BR0010084A (pt) * 1999-04-28 2002-01-15 Takeda Chemical Industries Ltd Composição farmacêutica, processos para prevenir, tratar ou inibir o desenvolvimento de retinopatia simples ou retinopatia proliferativa, e para aumentar potencial retiniano ou edema retiniano de mamìfero, e, uso de um composto
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
SK14642002A3 (sk) * 2000-04-12 2003-05-02 Novartis Ag Kombinované farmaceutické prostriedky obsahujúce antagonistu AT1-receptora a/alebo inhibítor HMG-CoA reduktázy a/alebo ACE inhibítor
EP1450793A2 (de) * 2001-11-23 2004-09-01 Solvay Pharmaceuticals GmbH Hypertoniebehandlung während der akuten phase des schlaganfalls
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
US20060014839A1 (en) * 2002-05-17 2006-01-19 Califf Robert M Combination of angiotensin II receptor blocker and beta-blocker for secondary prevention of myocardial infarction
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
PL377344A1 (pl) 2003-01-31 2006-01-23 Sankyo Company, Limited Lekarstwo do profilaktyki i leczenia miażdżycy tętnic i nadciśnienia
WO2009013760A2 (en) 2007-07-25 2009-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101333216A (zh) * 2008-08-03 2008-12-31 浙江华海药业股份有限公司 一种新的依普罗沙坦甲磺酸盐成盐工艺
CN113354553B (zh) * 2021-06-03 2023-09-15 北京宝诺康医药科技有限公司 一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
AU9137791A (en) * 1990-12-14 1992-07-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acids

Also Published As

Publication number Publication date
DE69721749T2 (de) 2004-03-25
TR199801954T2 (xx) 1998-12-21
PL188816B1 (pl) 2005-04-29
IL126319A0 (en) 1999-05-09
JP2000508632A (ja) 2000-07-11
CA2250395A1 (en) 1997-10-09
ES2198564T3 (es) 2004-02-01
NO311760B1 (no) 2002-01-21
EG23889A (en) 2007-12-12
SK282346B6 (sk) 2002-01-07
AP9700956A0 (en) 1997-04-30
AP901A (en) 2000-11-23
CN1214682A (zh) 1999-04-21
JP4316013B2 (ja) 2009-08-19
EA199800873A1 (ru) 1999-02-25
TW434239B (en) 2001-05-16
HU228263B1 (en) 2013-02-28
OA11176A (en) 2003-05-13
ATE239723T1 (de) 2003-05-15
BG102822A (en) 1999-11-30
BG64095B1 (bg) 2003-12-31
CZ293345B6 (cs) 2004-04-14
DE69721749D1 (de) 2003-06-12
MY117682A (en) 2004-07-31
UY24504A1 (es) 1997-09-19
DZ2199A1 (fr) 2002-12-03
AU2547097A (en) 1997-10-22
RO118870B1 (ro) 2003-12-30
EA001958B1 (ru) 2001-10-22
EP0889880B1 (en) 2003-05-07
ZA972686B (en) 1997-09-29
NZ332008A (en) 1999-05-28
NO984503L (no) 1998-09-28
EP0889880A1 (en) 1999-01-13
SK132298A3 (en) 1999-03-12
BR9708336A (pt) 1999-08-03
HK1016594A1 (en) 1999-11-05
UA49880C2 (uk) 2002-10-15
HUP9902769A2 (hu) 2000-03-28
CZ310198A3 (cs) 1999-03-17
CN1332167A (zh) 2002-01-23
AR006439A1 (es) 1999-08-25
DK0889880T3 (da) 2003-09-01
EP0889880A4 (en) 1999-06-23
NO984503D0 (no) 1998-09-28
MA24437A1 (fr) 1998-10-01
PT889880E (pt) 2003-09-30
PL329046A1 (en) 1999-03-01
AU726694B2 (en) 2000-11-16
WO1997036874A1 (en) 1997-10-09
ID16507A (id) 1997-10-02
CA2250395C (en) 2005-09-06
NO2002005I1 (no) 2002-09-02

Similar Documents

Publication Publication Date Title
EG23889A (en) Eprosartan dihydrate and a process for its production and formulation
HUP0001949A3 (en) Refastenable packing and process for manufacturing refastenable packing
IL133195A0 (en) Nonsteroidal gestagen compounds and processes for their production
HUP9903454A3 (en) A crystalline form of cefditoren pivoxyl and process for the production of the same
HUP9603112A3 (en) New pharmaceutical formulation and process for its production
EP1047407A4 (en) METHOD FOR PRODUCING A COUTINE TABLET
IL131298A0 (en) A pharmaceutical composition and a process for producing the same
HUP0000066A3 (en) Olanzapine dihydrate and process for preparing olanzapine form ii
EP0941668A4 (en) SORBETS AND THEIR MANUFACTURING METHODS
IL125194A0 (en) Process for manufacturing felodipine
GB9605597D0 (en) Process for making confectionery
HK1031688A1 (en) Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
GB9819651D0 (en) Matrerial and process for its production
PL347658A1 (en) Vancoresmycin, a process for its production and its use as a pharmaceutical
SI0889880T1 (en) Eprosartan dihydrate and a process for its production and formulation
HUP0102370A3 (en) Mumbaistatin, a process for its production and its use as a pharmaceutical
GB2317322B (en) A biscuit manufacturing process
GB9602805D0 (en) Production process
HU9701137D0 (en) Process for producing pharmaceutical intermedier
GB9709762D0 (en) Production process
SI1027047T1 (sl) Arginil kompleks eprosartana za nevtralizacijo naboja in postopek za njegovo izdelavo in formulacijo
GB9711802D0 (en) Process for confectionery production
GB9615770D0 (en) Production process
GB9604097D0 (en) Production process
HU9800144D0 (en) Artifically growed dripstone and process for production thereof